Drugs / Oil Palm Phenolics
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04164446 | Dec 2019 → Apr 2020 | cardiovascular disorder, hyperlipidemia | National University of Malaysia | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04573218 | Oct → Dec 2021 | hyperlipidemia | Isa Naina Mohamed | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oil Palm Phenolics | “Oil Palm Phenolics 250 mg” NCT04164446 ↗1“250 mg Oil Palm Phenolics” NCT04573218 ↗ |
| Known as | OPP | “The subjects were randomly distributed to two treatment arms with 25 participants each: control/placebo (11 males and 14 females) and 250 mg of OPP (10 males and 15 females).” PMID 37484009 ↗ Jul 20231“confirmed that the aqueous extract enriched in phenolics and other bioactives collectively known as oil palm phenolics (OPP) is safe and has potent bioactivity.” PMID 29844318 ↗ May 2018 |
| Route | Oral | “subjects were required to consume four capsules simultaneously per day.” PMID 35795564 ↗ Jun 2022 |